Gemphire Therapeutics (GEMP): Raising PT To $17 On Stronger Data - Jefferies

October 17, 2016 8:36 AM EDT
Get Alerts GEMP Hot Sheet
Price: $10.00 --0%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 29 | New: 6
Trade GEMP Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Matthew Andrews, reiterated his Buy rating on shares of Gemphire Therapeutics (NASDAQ: GEMP) and raised his price target to $17 from $15 after the Phase II(b) gemcabene program appears to be on track with dosing of first HoFH patient, two other Ph. II(b)’s to start by late Q4 2016/Q1 2017, and interim HoFH data in early 2017.

The analyst stated "we see ESPR's amended ETC-1002 strategy of also pursuing the high-dose statin HeFH/ASCVD markets as validation of GEMP's clinical/ regulatory strategy".

For an analyst ratings summary and ratings history on Gemphire Therapeutics click here. For more ratings news on Gemphire Therapeutics click here.

Shares of Gemphire Therapeutics closed at $10.11 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment